Advertisement

Topics

Oxford Immunotec Reports Second Quarter 2016 Financial Results

09:00 EDT 2 Aug 2016 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Second quarter revenue of $19.2 million, increased 34% compared to prior year period Raising revenue guidance for the full year from $79.5-$82.5 million to $82.5-$84.5 million Completed acquisition of Imugen, Inc. on July 1, 2016 for $2...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Oxford Immunotec Reports Second Quarter 2016 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...